JS212 Combination Therapies in Metastatic Colorectal Cancer

This is an open-label, multicenter Phase 2 clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS212-based combination therapies in patients with metastatic colorectal cancer (mCRC). JS212 is a bispecific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and HER3 with a topoisomerase I inhibitor payload. Preclinical and early clinical data suggest that dual targeting of EGFR and HER3 may enhance antitumor activity and overcome resistance mechanisms associated with EGFR- or HER2-directed therapies. This stud

Trial Details

NCT ID

NCT07503756

Phase

PHASE2

Sponsor

Shanghai Junshi Bioscience Co., Ltd.

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

JS212
Capecitabine
Bevacizumab
Oxaliplatin
JS207

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

1Participants must meet the following key criteria
Adults aged 18-75 years with histologically confirmed metastatic colorectal adenocarcinoma
Microsatellite stable (MSS) or mismatch repair proficient (pMMR) disease
No prior systemic therapy for advanced or metastatic disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →